Forrester To Recognise B2B Return On Integration Honours And B2B Programmes Of The Year Awards Winners At B2B Summit EMEA 2025
3.9.2025 11:00:00 CEST | Business Wire | Press Release
Forrester (Nasdaq: FORR) will recognise Thoughtworks as the 2025 recipient of its B2B Return On Integration (ROI) Honours at B2B Summit EMEA, taking place 6–8 October 2025 in London. The organisation will be recognised for optimising its go-to-market (GTM) approach to improve client retention and expansion by introducing AI-enabled analysis and reporting. Forrester will also honour this year’s B2B Programmes Of The Year (POY) Awards winner, AVEVA, for aligning its marketing, sales, and customer success functions to deliver and scale personalised, insight-driven experiences through its account-based marketing (ABM) strategy. These awards recognise firms that prove alignment rooted in customer value and growth can deliver tangible business outcomes.
B2B Summit EMEA is the premier event for B2B marketing and sales leaders to access new research, proven frameworks, and best practices that advance cross-functional alignment. The programme equips leaders with the tools needed to navigate shifting buyer expectations, the rising influence of AI, and ongoing economic uncertainty.
This year’s B2B ROI Honours winner, Thoughtworks, a global technology consultancy, enhanced its go-to-market efforts by launching a multi-agent marketing insights application built on a martech stack and data architecture reengineered for agents. This application provides real-time reporting with a conversational generative AI interface, based on a unified key performance indicator framework. In its keynote session, Thoughtworks will discuss how it utilised Forrester’s frameworks and research that enabled a shift toward contextual genAI-powered reporting and insights agents. As a result, the GTM organisation is more tightly aligned to the company’s growth priorities, achieving higher win rates and measurable gains in retention and client expansion.
“Like most companies, we relied on manual reporting via CRM systems and dashboards to drive marketing ROI,” said Julie Woods-Moss, chief marketing officer at Thoughtworks. “Now, we operate with AI-powered real-time performance data and reasoning. Rewiring our tech stack for agents and rearchitecting our data was an important first step to building an agentic marketing organisation. Conversational genAI enables marketers to have both real-time data and insightful reasoning. Early benefits include improved win rates, buying group expansion, and better allocation of resources. We are continually looking for ways to improve our go-to-market performance, and it is encouraging to see the rapid adoption of AI agents across marketing at Thoughtworks.”
The B2B POY Awards winner, AVEVA, will also discuss its shift from being a fragmented marketing organisation to operating as a fully integrated ABM personalisation engine that has transformed enterprise account engagement.
“Thoughtworks and AVEVA exemplify how disciplined cross-functional alignment translates into measurable business impact,” said Paul Ferron, VP and research director at Forrester. “At B2B Summit EMEA, attendees will hear how these leaders are reshaping their B2B strategy for growth during this era of volatility.”
Resources:
- Register to attend B2B Summit EMEA.
- Follow Forrester on LinkedIn and #ForrB2BSummit for updates.
- View the full agenda and speakers.
About Forrester
Forrester (Nasdaq: FORR) is one of the most influential research and advisory firms in the world. We empower leaders in technology, customer experience, digital, marketing, sales, and product functions to be bold at work and accelerate growth through customer obsession. Our unique research and continuous guidance model helps executives and their teams achieve their initiatives and outcomes faster and with confidence. To learn more, visit Forrester.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250903298055/en/
Contacts
Press:
Hannah Segvich
hsegvich@forrester.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom